SINGAPORE - Barely three months after the front-runner Pfizer-BioNTech Covid-19 vaccine was rolled out in a mass vaccination campaign in Britain, some vaccine developers are already redesigning their vaccines to tackle new variants.
Last week, United States biotechnology firm Moderna announced that it had dosed the first participant in a trial evaluating a booster vaccine it designed to target a new variant of the virus first identified in South Africa.
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
